CLAIMS:

1. The use of anti-CD38 antibody in the manufacture of a composition for treating multiple myeloma in a subject wherein said composition is for administration with a lenalidomide compound,

   wherein the subject has undergone at least two prior therapies for multiple myeloma and at least one of the two prior therapies for multiple myeloma was an immunomodulatory drug, and

   wherein the anti-CD38 antibody comprises a heavy chain comprising three sequential CDRs comprising amino acid sequences of SEQ ID NOs: 13, 81, and 15, and a light comprising three sequential CDRs comprising amino acid sequences of SEQ ID NOs: 16, 17, and 18.

2. The use of claim 1, wherein the immunomodulatory drug is selected from the group consisting of: a lenalidomide compound or thalidomide.

3. The use of claim 1 or 2, wherein the lenalidomide compound is lenalidomide.

4. The use of any one of claims 1 to 3, wherein the anti-CD38 antibody is capable of killing a $CD38^+$ cell by apoptosis, antibodydependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

5. The use of any one of claims 1 to 4, wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 66, and a light chain variable region comprising the amino acid sequence set forth in either SEQ ID NO: 62 or SEQ ID NO: 64.

6. The use of any one of claims 1 to 5, wherein the anti-CD38 antibody is administered intravenously.

7. The use of any one of claims 1 to 6, wherein the lenalidomide compound is administered orally.

8. The use of any one of claims 1 to 7, wherein the anti-CD38 antibody and the lenalidomide compound are administered sequentially.

9. The use of any one of claims 1 to 8, further comprising administering a dexamethasone compound, preferably dexamethasone, to the subject.

10. The use of claim 9, wherein the dexamethasone compound is administered orally.

11. The use of claim 9 or 10, wherein the dexamethasone compound is administered at a low dose.

12. The use of any one of claims 9 to 11, wherein the anti-CD38 antibody, the lenalidomide compound, and the dexamethasone compound are administered sequentially.

13. The use of any one of claims 1 to 8, further comprising administering an anticoagulation agent to the subject.

14. The use of claim 13, wherein the anti-CD38 antibody, the lenalidomide compound, and the anti-coagulation agent are administered sequentially.

15. The use of any one of claims 9 to 12, further comprising administering an anticoagulation agent to the subject.

16. The use of claim 15, wherein the anti-CD38 antibody, the lenalidomide compound, the dexamethasone compound, and the anti-coagulation agent are administered sequentially.

17. The use of any one of claims 13-16, wherein the anti-coagulation agent is selected from the group consisting of: aspirin, warfarin, and low molecular weight heparin.

18. A kit when used in the use of any one of claims 1 to 17, said kit comprising

a) a first composition comprising an anti-CD38 antibody that comprises a heavy chain comprising three sequential CDRs having amino acid sequences of SEQ ID NOs: 13, 81, and 15, and a light comprising three sequential CDRs having amino acid sequences of SEQ ID NOs: 16, 17, and 18; and

b) a second composition comprising a lenalidomide compound.

19. The kit of claim 18, wherein the lenalidomide compound is lenalidomide.

20. The kit of claim 18 or 19, wherein the first and second compositions are packaged for sequential administration to a subject.

21. The kit of any one of claims 18 to 20 further comprising a composition comprising a dexamethasone compound.

22. The kit of claim 21, wherein the dexamethasone compound is dexamethasone.

23. The kit of claim 21 or 22, wherein the dexamethasone compound is packaged for sequential administration to a subject.

24. The kit of any one of claims 18 to 23, further comprising an anti-coagulation agent.

25. The kit of claim 24, wherein the anti-coagulation agent is packaged for sequential administration to a subject.